Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227703 · ClinicalTrials.gov registry record · Phase 2
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
NCT05227703: Completed Phase 2 study, sponsored by AbbVie.
NCT05227703 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 391 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (194% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227703, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Primary Outcome
The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Da
Interventions
- DRUG Placebo
- DRUG Emraclidine 30 mg
- DRUG Emraclidine 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-09-11 |
| Phase | Phase 2 |
What the finished NCT05227703 record still lists
NCT05227703 is an interventional study that assigns participants to a tested intervention. The registered 391 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (194% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05227703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05227703 about?
NCT05227703 is a clinical study titled "A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experie...
What is the current status of trial NCT05227703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2022-07-05. Estimated completion is 2024-09-11.
What interventions are being tested in trial NCT05227703?
The interventions under investigation include: Placebo (DRUG), Emraclidine 30 mg (DRUG), Emraclidine 15 mg (DRUG).
Who is sponsoring clinical trial NCT05227703?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05227703's enrollment target sits among peer trials
391 106th of 2000 higher than 1,895 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI